PATENT CLAIM ANALYSIS

Application Number: 15904254
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["530", "350000"]

Abstract:
Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

Claim (Index 17):
The composition of  claim 16 , wherein the erythrocyte-binding moiety has the ability to bind Band 3 (CD233), glycophorin-A, glycophorin B (CD235b), glycophorin C(CD235c), or glycophorin D (CD235d) with an affinity generating a dissociation constant of between about 10 \u03bcM and 0.1 nM as determined by equilibrium binding measurements between the erythrocyte-binding moiety and erythrocytes.

Metadata:
- Claim Count in Document: 51.0
- Percentile: 88.0
- Lexical Diversity: 1.38182
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15232713', '15904248', '15904228', '15232724', '15232714']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8328248195190058
- 35 USC 102 Novelty (BERT): 0.7035660464209081
- Combined Prediction Score: 0.819898942209196
- Mean Citation Score: 727.8368780000003
- Max Citation Score: 790.30615
- Similarity Product: 726.9623990069658

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test